VWV, a prominent national law firm, strengthens its Pharma & Life Sciences team by welcoming Harry Hamilton Jennings as Partner.
- Harry Jennings transitions from entrepreneurship back to private practice with broad industry experience.
- His experience includes a role as lead knowledge lawyer in Practical Law’s life sciences division.
- Paul Gershlick of VWV anticipates Jennings’ contributions to early-stage companies and incubators.
- VWV continues to drive innovation and support within the life sciences sector.
VWV, a well-regarded national law firm, has announced the appointment of Harry Hamilton Jennings as a Partner, significantly enhancing its Pharma & Life Sciences division. Having previously founded Hamilton Law Scientific, Jennings brings extensive knowledge and experience back into private practice, aiming to support the firm’s ongoing mission to offer expansive services to life sciences clients.
Harry Jennings expressed enthusiasm about joining VWV, noting the rapidly evolving nature of the life sciences industry, particularly with impending major UK and EU reforms. He sees significant potential in forging strong connections with key life sciences clusters across Southern and Central UK, utilising his impressive industry knowledge to guide clients from initial market entry through to subsequent stages.
Before this appointment, Jennings served as the lead knowledge lawyer for Practical Law’s life sciences segment, where he developed valuable tools such as contract templates and practice notes that are widely used by sector professionals. His previous experience also includes critical roles within the life sciences legal teams of Pennington Manches in Oxford and Patheon, Swindon—part of Thermo Fisher Scientific.
Working from his home base in Wiltshire, Jennings aims to revitalise connections within the local industry as well as the broader Thames Valley area. His objective encompasses fostering relationships with regional businesses while sharing his profound expertise to nurture emerging companies in the sector.
Paul Gershlick, lead of VWV’s Pharmaceuticals & Life Sciences sector, voiced strong support for Jennings’ integration into the team, citing his knowledge and experience as pivotal assets. Gershlick is particularly optimistic about Jennings’ ability to augment the support provided to early-stage businesses and innovation hubs, reinforcing VWV’s status as a leader in this vibrant field.
VWV’s commitment to the life sciences arena is well-illustrated by initiatives such as its celebrated Pharmaceutical Industry Networking Group (PING), which hosts conferences with key industry leaders and influencers. By bringing aboard Jennings, VWV reinforces its strategic vision to further grow its influence and capabilities within this dynamic sector.
Harry Jennings’ arrival at VWV marks a strategic enhancement of the firm’s capabilities in the life sciences sector, promising to boost support and innovation across the industry.
